Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AICDA (Activation-induced cytidine deaminase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AICDA Recombinant Protein / Mutants High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Intracellular target optimized. |
View AICDA Products |
| Gene Delivery | AICDA Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View AICDA Products |
| Benchmark Ab | Anti-AICDA Antibody Recombinant positive control for western blot and target engagement. |
View AICDA Products |
| Validator | AICDA siRNA Set For knockdown verification and specificity checks. |
View AICDA Products |
| Related Target A | UNG Synergistic pathway downstream of AICDA in DNA repair and somatic hypermutation. |
View UNG Products |
| Related Target B | APOBEC3G Critical family member for selectivity counter-screening against off-target editing. |
View APOBEC3G Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against APOBEC family | Homolog panel proteins (APOBEC family) strictly verified by mass spec and sequence analysis. |
| Enzymatic Assay Stability | Recombinant AICDA expressed with native-like folding protocols; High Purity (>95%) for reliable biochemical assays. |
| Lack of Validated Controls | Sequence-verified positive control antibodies included for expression tracking. |
| False Positives in Phenotypic Screens | Validated siRNA included for genetic specificity checks in B-cell models. |
Live AICDA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AICDA therapeutics is intensifying as researchers recognize its critical role in tumor evolution and drug resistance. Originally studied for its role in antibody diversification via somatic hypermutation (SHM) and class switch recombination (CSR), aberrant AICDA expression in B-cells drives oncogenic translocations (e.g., c-MYC, BCL6) and continuously mutates drug targets, leading to therapy-refractory leukemias and lymphomas. As first-generation small molecule inhibitors enter preclinical evaluations, the next wave of R&D is heavily targeting Targeted Protein Degradation (PROTACs) to completely remove the intracellular pathogenic enzyme rather than relying on occupancy-driven catalytic inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Spin-offs, Specialized Biotechs | B-cell Lymphomas (DLBCL, Burkitt's) | Enzymatic Assay (Need high-purity recombinant AICDA protein) |
| PROTAC / Degrader | Targeted Protein Degradation Innovators | Refractory Leukemia, Autoimmune | Ternary Complex Formation (Need highly stable WT/Mutant proteins) |
| RNAi / ASO | Oligonucleotide Therapeutics Cos | Systemic Lupus Erythematosus (SLE) | Knockdown Validation (Need standardized cell lines and baseline validation) |